Erytech shares soar on positive results for PhIIb pancreatic cancer trial; ArQule’s tivantinib fails yet again in PhIII cancer study
→ France’s Erytech Pharma says it garnered positive data in a Phase IIb study of eryaspase combined with chemo for second-line metastatic pancreatic cancer, sending shares $ERYP rocketing up 75%. The drug hits its co-primary endpoints with significant improvements for progression-free survival as well as overall survival. Pascal Hammel, principal investigator of the study, commented: “These results generated by eryaspase in combination with the standard of care are highly encouraging and compare favorably to gemcitabine or FOLFOX treatment administered alone. The results of this study support eryaspase as a potential treatment option for patients with metastatic pancreatic cancer in the second-line setting.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.